Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 21,042 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ONE Clear all

Conditions: Healthy Participants
Interventions: AZD6234, Placebo, Acetaminophen; Drug · Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Anesthesia
Interventions: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%; Drug
Lead sponsor: St. Renatus, LLC; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Stroke
Interventions: IV rt-PA alone, endovascular therapy; Drug · Other
Lead sponsor: Joseph Broderick; Other
Eligibility: 18 Years to 82 Years
Enrollment: 656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 49
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 39 more

Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions: CTLA4-IgG4m (RG2077), Cyclophosphamide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Pembrolizumab, Cisplatin, IMRT; Drug · Radiation
Lead sponsor: Dan Zandberg; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Obesity, Overweight, or Chronic Weight Management
Interventions: Aleniglipron or Placebo, Aleniglipron; Drug
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 39
States / cities: Phoenix, Arizona • Anaheim, California • Los Angeles, California + 33 more

Conditions: Plaque Psoriasis, Psoriasis Vulgaris
Interventions: Taclonex Ointment and Hydrogel Patch, Taclonex Ointment; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Low Back Pain
Interventions: Acetaminophen, Ibuprofen 600 mg, Educational intervention, Placebo oral capsule; Drug · Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 69 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
Interventions: Encorafenib Pill, Binimetinib Pill, Nivolumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
Interventions: Galunisertib 150mg by mouth twice a day, Stereotactic Body Radiotherapy (SBRT); Drug · Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Smoking Cessation
Interventions: Qualitative Group Interviews, Stakeholder advisory group; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Learning Problems
Interventions: LearningRx cognitive training; Behavioral
Lead sponsor: Gibson Institute of Cognitive Research; Industry
Eligibility: 8 Years to 14 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Conditions: Analgesia, Obstetrical, Obstetric Surgical Procedures
Interventions: Morphine, Hydromorphone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Periodontitis
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 34 Years to 55 Years
Enrollment: 5,117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Metastatic Anaplastic Thyroid Cancer
Interventions: durvalumab, tremelimumab, Stereotactic Body Radiotherapy (SBRT); Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: AR11, Placebo; Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 7
States / cities: Bradenton, Florida • Maitland, Florida • South Miami, Florida + 3 more

Conditions: Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level, IDH2 Gene Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Enasidenib, Hematopoietic Cell Transplantation; Drug · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Buffalo, New York • East Hills, New York

Conditions: Human Immunodeficiency Virus
Interventions: 10-1074-LS, 3BNC117-LS; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Small Cell Lung Cancer
Interventions: Cabozantinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Lung Cancer
Interventions: Six-Minute Walk Test, Exercise stress test; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sarcoma, Soft Tissue Sarcoma, Metastatic Sarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Leiomyosarcoma, Liposarcoma, Angiosarcoma, Synovial Sarcoma, Rhabdomyosarcoma, Spindle Cell Sarcoma, High Grade Sarcoma, Bone Sarcoma
Interventions: Gemcitabine, Docetaxel, 9-ING-41; Drug
Lead sponsor: Brown University; Other
Eligibility: 10 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Refractory Neuroblastoma, Relapsed Neuroblastoma, High-Risk Neuroblastoma
Interventions: PHOX2B PC-CAR T Cells; Biological
Lead sponsor: Stephan Grupp MD PhD; Other
Eligibility: 1 Year and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Fibromyalgia Syndrome
Interventions: RSA Biofeedback, EEG Biofeedback Condition; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer, Virtual Reality, Trastuzumab
Interventions: Cardiovascular Health Education and Gaming through Virtual Reality; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Richmond, Virginia

Search by objective public record fields.

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

Safety and Pharmacokinetics of Kovacaine Nasal Spray in Pediatric Subjects

Interventional Management of Stroke (IMS) III Trial

Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)

Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer

A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis

Ibuprofen With or Without Acetaminophen for Low Back Pain

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)

Designing an Implementation Strategy for Lung Screening and Smoking Cessation Treatment in Community Health Centers

LearningRx Brain Training for Children 8-14

Spinal Morphine vs. Hydromorphone for Pain Control After Cesarean Delivery

Periodontal Disease Prevention Study

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Six-Minute Walk Test in Patients at High Risk for Complications From Lung Resection

A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

HRV Biofeedback in Fibromyalgia

Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab